- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00190151
Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora
September 17, 2012 updated by: Assistance Publique - Hôpitaux de Paris
Pharmacokinetic/Pharmacodynamic Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora
Bacterial resistance to antibiotics has been a growing therapeutic problem since the late 1980s.
Resistant strains of pathogenic bacteria can arise through initial selection of resistant strains in the commensal flora.
The emergence of fluoroquinolone resistance in the commensal flora will be assessed in 48 healthy volunteers receiving variable doses of ciprofloxacin during 14 days.
Emergence of resistance will be correlated to pharmacokinetic characteristics of ciprofloxacin.
Study Overview
Detailed Description
Pharmacokinetic/Pharmacodynamic Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora Bacterial resistance to antibiotics has been a growing therapeutic problem since the late 1980s.
Resistant strains of pathogenic bacteria can arise through initial selection of resistant strains in the commensal flora.
The emergence of fluoroquinolone resistance in the commensal flora will be assessed in 48 healthy volunteers receiving variable doses of ciprofloxacin during 14 days.
Emergence of resistance will be correlated to pharmacokinetic characteristics of ciprofloxacin.
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75877
- Hôpital Bichat Claude Bernard, 46 rue Henri Huchard
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- healthy volunteers
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Occurrence of bacterial resistance in commensal flora
|
Secondary Outcome Measures
Outcome Measure |
---|
Pharmacokinetic/pharmacodynamic relationship
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Bruno Fantin, Hôpital Beaujon, 100 boulevard du Général Leclerc, 92110 Clichy, France
- Principal Investigator: Xavier Duval, Hôpital Bichat Claude Bernard, 48 rue Henri Huchard, 75877 Paris Cedex 18, France
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- de Lastours V, Maugy E, Mathy V, Chau F, Rossi B, Guerin F, Cattoir V, Fantin B; CIPHARES Study Group. Ecological impact of ciprofloxacin on commensal enterococci in healthy volunteers. J Antimicrob Chemother. 2017 Jun 1;72(6):1574-1580. doi: 10.1093/jac/dkx043.
- de Lastours V, Cambau E, Guillard T, Marcade G, Chau F, Fantin B. Diversity of individual dynamic patterns of emergence of resistance to quinolones in Escherichia coli from the fecal flora of healthy volunteers exposed to ciprofloxacin. J Infect Dis. 2012 Nov;206(9):1399-406. doi: 10.1093/infdis/jis511. Epub 2012 Aug 28.
- Fantin B, Duval X, Massias L, Alavoine L, Chau F, Retout S, Andremont A, Mentre F. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis. 2009 Aug 1;200(3):390-8. doi: 10.1086/600122.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2004
Primary Completion (Actual)
July 1, 2005
Study Completion (Actual)
July 1, 2005
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 19, 2005
Study Record Updates
Last Update Posted (Estimate)
September 18, 2012
Last Update Submitted That Met QC Criteria
September 17, 2012
Last Verified
September 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P031007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on ciprofloxacin
-
University of FloridaTerminatedAcute Myeloid Leukemia | Leukemia | Acute Myelogenous LeukemiaUnited States
-
MerLion Pharmaceuticals GmbHCompletedUrinary Tract Infections | Acute PyelonephritisGermany
-
Guohua ZengUnknown
-
BayerCompletedBacterial InfectionsUnited States, Spain, Italy, Canada, Brazil, Mexico
-
Otonomy, Inc.Completed
-
BayerCompletedUrinary Tract InfectionItaly
-
Kaiser PermanenteCompletedPancreatic CystsUnited States
-
Otic PharmaCompletedOtorhinolaryngologic Diseases | Ear Diseases | Otitis Externa | OtitisIsrael
-
Mount Sinai Hospital, CanadaCrohn's and Colitis FoundationTerminated
-
Aradigm CorporationGrifols Therapeutics LLCCompletedNon Cystic Fibrosis BronchiectasisUnited States, Italy, Poland, Taiwan, United Kingdom, Germany, Spain, Israel, Romania, South Africa, Korea, Republic of, Australia, Canada, Hungary, Ireland, Latvia